The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .
Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients.
In order to assess the efficacy of gemfibrozil on lipid and haemostatic parameters in patients with plurimetabolic syndrome , a multicenter double-blind placebo controlled , parallel study was carried out in 56 patients with primary hypertriglyceridemia and glucose intolerance . These patients had elevated PAI activity and antigen and t-PA antigen levels at rest and after venous occlusion . Gemfibrozil reduced plasma triglyceride levels ( P<0.001 ) , whereas it increased free fatty acids ( P<0.05 ) and high density lipoprotein cholesterol levels ( P<0.05 ) . In those patients reaching normalization of plasma triglyceride levels ( triglyceride reduction > or = 50 % ) ( n=15 ) , insulin levels ( P<0.05 ) as well as the insulin resistance index were reduced by gemfibrozil treatment , suggesting an improvement of the insulin resistance index in this patient subgroup . Gemfibrozil treatment did not affect plasma fibrinolysis or fibrinogen levels , despite marked reduction of plasma triglycerides and improvement of the insulin sensitivity associated with triglyceride normalization
The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .